Myasthenia gravis CT
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Keanu Ngo[2]
|
Myasthenia gravis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Myasthenia gravis CT On the Web |
|
American Roentgen Ray Society Images of Myasthenia gravis CT |
Overview
Chest computed tomography (CT) is the primary imaging modality for evaluating the thymus in myasthenia gravis (MG). Baseline cross-sectional imaging with CT or MRI is required in all newly diagnosed MG patients to screen for thymoma, which is present in approximately 15% of patients at onset.[1][2] Initial CT correctly identifies roughly 90% of thymomas with a specificity of ~95%.[1] However, CT cannot reliably differentiate a small thymoma from focal thymic lymphoid hyperplasia (TLH), nor can it reliably distinguish TLH from a normal gland.[3][4]
CT
Rationale and Disease Context
Thymic abnormalities are highly prevalent in MG:
- Thymic Lymphoid Hyperplasia (TLH): Present in up to ~65% of MG patients.[5]
- Thymoma: Present in ~15% of patients at presentation.[2] Thymoma is almost exclusively confined to anti-acetylcholine receptor (AChR) antibody-positive disease and is extremely rare in AChR-negative or anti-muscle-specific kinase (MuSK) antibody-positive MG.[1]
Despite antibody subgroup variations, baseline CT or MRI screening remains essential in all patients.[1][2] Striational (anti-titin/RyR) antibodies do not replace CT for predicting thymoma, as ~45% of MG patients with thymoma test negative for striational antibodies.[1][6]
Diagnostic Accuracy and Limitations
In a landmark surgical cohort of 154 MG patients, CT demonstrated a sensitivity of 85%, specificity of 98.7%, and overall accuracy of 95.8% for thymoma detection, significantly outperforming plain radiography (58%).[7] False negatives occurred predominantly with tiny tumors obscured by adjacent thymic parenchyma or motion artifacts.[7]
Detection sensitivity is strongly age-dependent due to physiological thymic involution:[7]
- Age ≤20 years (Thymoma prevalence ~3%): High parenchymal density can mask small intramural tumors.
- Age 21–45 years (Thymoma prevalence ~12%): Incomplete fatty involution creates residual islands of tissue that mimic or obscure lesions.
- Age >45 years (Thymoma prevalence ~35%): Advanced fatty involution enhances the radiologic contrast of small soft-tissue masses.
CT Interpretation and Imaging Morphology
| Suspected Pathology | CT Imaging Features |
|---|---|
| Thymoma | Well-defined, round or oval, soft-tissue mass within the anterior mediastinum. Demonstrates homogeneous or marked enhancement.[5][8] Calcifications (rim or punctate) are seen in ~12% of cases.[7] |
| Thymic Hyperplasia (TLH) | Diffuse, symmetrical gland enlargement maintaining a normal triangular/quadrangular contour with interspersed fat.[5][8] May occasionally present as a nodular or focal mass-like lesion mimicking thymoma.[4] |
| Thymic Carcinoma / Invasive Neoplasm | Large, poorly circumscribed, heterogeneous anterior mediastinal mass with direct local tissue invasion, mediastinal lymphadenopathy, or pleural/pericardial effusions.[9] |
Key Diagnostic Pitfall: CT cannot reliably differentiate mass-like focal hyperplasia from a low-risk thymoma; in surgical series, up to 40–50% of focal CT "masses" corresponded to hyperplasia rather than neoplasm.[4] A mean thymic radiodensity cutoff of ~20 HU discriminates thymoma from non-thymomatous conditions (AUROC 0.904, accuracy 77%), but chemical-shift MRI is significantly more accurate (signal-intensity-index cutoff 7.77%, AUROC 0.989, accuracy 96%); equivocal CT cases should be evaluated with chemical-shift MRI.[10]
Non-Contrast vs. Contrast-Enhanced CT Protocols
A minor guideline tension exists between initial neurological evaluation and thoracic oncology staging protocols:
- Initial Screening: Non-contrast chest CT is often favored as the initial screening study in MG neurology reviews.[1][3] Non-contrast acquisition provides high sensitivity for detecting the presence of a mediastinal mass while avoiding potential contrast-induced disease exacerbation.[1][3]
- Tumor Characterization & Staging: National Comprehensive Cancer Network (NCCN) guidelines list chest CT with contrast as the core workup study for an anterior mediastinal mass, used to assess tumor margins, vascular involvement, and local invasion; chest MRI with and without contrast is added as clinically indicated and may discriminate thymic malignancy from cyst or hyperplasia better than CT, potentially avoiding an unnecessary thymectomy.[11]
Iodinated Contrast Safety in Myasthenia Gravis
The safety of intravenous iodinated contrast media in patients with MG remains a nuanced clinical topic:
- Exacerbation Signal: A retrospective cohort study of 267 MG patients demonstrated significantly more disease-related exacerbations within 24 hours following contrast-enhanced CT than non-contrast CT (6.3% [7/112] vs 0.6% [1/155], p=0.01); acute exacerbations were predominantly respiratory (new or progressive dyspnea).[12]
- Counterbalancing Evidence: A separate retrospective cohort found delayed clinical worsening in a minority of MG patients after iodinated contrast but judged contrast to be a causative factor in essentially none, concluding contrast should not be withheld when clinically indicated.[13] The ACR Manual on Contrast Media (2025) reflects this uncertainty, stating that low-osmolality contrast may be relatively contraindicated in MG pending confirmatory studies.[14]
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 Punga AR, Maddison P, Heckmann JM, Guptill JT, Evoli A (2022). "Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders". Lancet Neurol. 21 (2): 176–188. doi:10.1016/S1474-4422(21)00297-0. PMID 34958509 Check
|pmid=value (help). - ↑ 2.0 2.1 2.2 Gilhus NE, Verschuuren JJ (2015). "Myasthenia gravis: subgroup classification and therapeutic strategies". Lancet Neurol. 14 (10): 1023–1036. doi:10.1016/S1474-4422(15)00145-3. PMID 26303280.
- ↑ 3.0 3.1 3.2 Klimiec E, Quirke M, Leite MI, Hilton-Jones D (2018). "Thymus imaging in myasthenia gravis: The relevance in clinical practice". Muscle Nerve. 58 (4): 707–713. doi:10.1002/mus.26075. PMID 29890786.
- ↑ 4.0 4.1 4.2 Nicolaou S, Müller NL, Li DK, Oger JJ (1996). "Thymus in myasthenia gravis: comparison of CT and pathologic findings and clinical outcome after thymectomy". Radiology. 201 (2): 471–474. doi:10.1148/radiology.201.2.8888243. PMID 8888243.
- ↑ 5.0 5.1 5.2 Priola AM, Priola SM (2014). "Imaging of thymus in myasthenia gravis: from thymic hyperplasia to thymic tumor". Clin Radiol. 69 (5): e230–e245. doi:10.1016/j.crad.2014.01.005. PMID 24529683.
- ↑ Shelly S, Mills JR, Dubey D, et al. (2021). "Clinical utility of striational antibodies in paraneoplastic and myasthenia gravis paraneoplastic panels". Neurology. 96 (24): e2966–e2976. doi:10.1212/WNL.0000000000012050. PMID 33980754 Check
|pmid=value (help). - ↑ 7.0 7.1 7.2 7.3 Ellis K, Austin JH, Jaretzki A (1988). "Radiologic detection of thymoma in patients with myasthenia gravis". AJR Am J Roentgenol. 151 (5): 873–881. doi:10.2214/ajr.151.5.873. PMID 3263017.
- ↑ 8.0 8.1 Dong W, Xiong S, Wang X, et al. (2023). "Development and validation of a contrast-enhanced CT-based radiomics nomogram for differentiating mass-like thymic hyperplasia and low-risk thymoma". J Cancer Res Clin Oncol. 149 (16): 14901–14910. doi:10.1007/s00432-023-05263-3. PMID 37368045 Check
|pmid=value (help). - ↑ Munden RF, Carter BW, Chiles C, et al. (2018). "Managing Incidental Findings on Thoracic CT: Mediastinal and Cardiovascular Findings. A White Paper of the ACR Incidental Findings Committee". J Am Coll Radiol. 15 (8): 1087–1096. doi:10.1016/j.jacr.2018.04.029. PMID 30030008.
- ↑ Priola AM, Priola SM, Gned D, et al. (2016). "Comparison of CT and chemical-shift MRI for differentiating thymoma from non-thymomatous conditions in myasthenia gravis". Clin Radiol. 71 (3): e157–e169. doi:10.1016/j.crad.2015.12.008. PMID 26774127.
- ↑ National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Thymomas and Thymic Carcinomas, Version 2.2026 (THYM-1).
- ↑ Somashekar DK, Davenport MS, Cohan RH, Dillman JR, Ellis JH (2013). "Effect of intravenous low-osmolality iodinated contrast media on patients with myasthenia gravis". Radiology. 267 (3): 727–734. doi:10.1148/radiol.13121280. PMID 23360741.
- ↑ Rath J, Berek K, Krenn M, et al. (2017). "Intravenous contrast media in myasthenia gravis: a retrospective cohort study". J Neurol. 264 (2): 240–245. doi:10.1007/s00415-016-8332-9. PMID 27921158.
- ↑ ACR Manual on Contrast Media 2025. ACR Committee on Drugs and Contrast Media. American College of Radiology.